tetano
Editor, Senior Moderator
Neurol Neuroimmunol Neuroinflamm
. 2022 Feb 1;9(2):e1143.
doi: 10.1212/NXI.0000000000001143. Print 2022 Mar.
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis
Ana Zabalza[SUP] 1 [/SUP], Georgina Arrambide[SUP] 2 [/SUP], Paula Tagliani[SUP] 2 [/SUP], Simón Cárdenas-Robledo[SUP] 2 [/SUP], Susana Otero-Romero[SUP] 2 [/SUP], Juliana Esperalba[SUP] 2 [/SUP], Candela Fernandez-Naval[SUP] 2 [/SUP], Jesus Trocoli Campuzano[SUP] 2 [/SUP], Mónica Martínez Gallo[SUP] 2 [/SUP], Mireia Castillo[SUP] 2 [/SUP], Mercè Bonastre[SUP] 2 [/SUP], Mireia Resina Sallés[SUP] 2 [/SUP], Jordina Beltran[SUP] 2 [/SUP], Pere Carbonell-Mirabent[SUP] 2 [/SUP], Marta Rodríguez-Barranco[SUP] 2 [/SUP], Samuel López-Maza[SUP] 2 [/SUP], Pedro José Melgarejo Otálora[SUP] 2 [/SUP], Mariano Ruiz-Ortiz[SUP] 2 [/SUP], Agustin Pappolla[SUP] 2 [/SUP], Breogán Rodríguez Acevedo[SUP] 2 [/SUP], Luciana Midaglia[SUP] 2 [/SUP], Angela Vidal-Jordana[SUP] 2 [/SUP], Alvaro Cobo-Calvo[SUP] 2 [/SUP], Carmen Tur[SUP] 2 [/SUP], Ingrid Galán[SUP] 2 [/SUP], Joaquín Castilló[SUP] 2 [/SUP], Jordi Río[SUP] 2 [/SUP], Carmen Espejo[SUP] 2 [/SUP], Manuel Comabella[SUP] 2 [/SUP], Carlos Nos[SUP] 2 [/SUP], Jaume Sastre-Garriga[SUP] 2 [/SUP], Mar Tintore[SUP] 2 [/SUP], Xavier Montalban[SUP] 2 [/SUP]
Affiliations
Abstract
Background and objectives: Information about humoral and cellular responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and antibody persistence in convalescent (COVID-19) patients with multiple sclerosis (PwMS) is scarce. The objectives of this study were to investigate factors influencing humoral and cellular responses to SARS-CoV-2 and its persistence in convalescent COVID-19 PwMS.
Methods: This is a retrospective study of confirmed COVID-19 convalescent PwMS identified between February 2020 and May 2021 by SARS-CoV-2 antibody testing. We examined relationships between demographics, MS characteristics, disease-modifying therapy (DMT), and humoral (immunoglobulin G against spike and nucleocapsid proteins) and cellular (interferon-gamma [IFN-γ]) responses to SARS-CoV-2.
Results: A total of 121 (83.45%) of 145 PwMS were seropositive, and 25/42 (59.5%) presented a cellular response up to 13.1 months after COVID-19. Anti-CD20-treated patients had lower antibody titers than those under other DMTs (p < 0.001), but severe COVID-19 and a longer time from last infusion increased the likelihood of producing a humoral response. IFN-γ levels did not differ among DMT. Five of 7 (71.4%) anti--CD20-treated seronegative patients had a cellular response. The humoral response persisted for more than 6 months in 41/56(81.13%) PwMS. In multivariate analysis, seropositivity decreased due to anti-CD20 therapy (OR 0.08 [95% CI 0.01-0.55]) and increased in males (OR 3.59 [1.02-12.68]), whereas the cellular response decreased in those with progressive disease (OR 0.04 [0.001-0.88]). No factors were associated with antibody persistence.
Discussion: Humoral and cellular responses to SARS-CoV-2 are present in COVID-19 convalescent PwMS up to 13.10 months after COVID-19. The humoral response decreases under anti-CD20 treatment, although the cellular response can be detected in anti-CD20-treated patients, even in the absence of antibodies.
. 2022 Feb 1;9(2):e1143.
doi: 10.1212/NXI.0000000000001143. Print 2022 Mar.
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis
Ana Zabalza[SUP] 1 [/SUP], Georgina Arrambide[SUP] 2 [/SUP], Paula Tagliani[SUP] 2 [/SUP], Simón Cárdenas-Robledo[SUP] 2 [/SUP], Susana Otero-Romero[SUP] 2 [/SUP], Juliana Esperalba[SUP] 2 [/SUP], Candela Fernandez-Naval[SUP] 2 [/SUP], Jesus Trocoli Campuzano[SUP] 2 [/SUP], Mónica Martínez Gallo[SUP] 2 [/SUP], Mireia Castillo[SUP] 2 [/SUP], Mercè Bonastre[SUP] 2 [/SUP], Mireia Resina Sallés[SUP] 2 [/SUP], Jordina Beltran[SUP] 2 [/SUP], Pere Carbonell-Mirabent[SUP] 2 [/SUP], Marta Rodríguez-Barranco[SUP] 2 [/SUP], Samuel López-Maza[SUP] 2 [/SUP], Pedro José Melgarejo Otálora[SUP] 2 [/SUP], Mariano Ruiz-Ortiz[SUP] 2 [/SUP], Agustin Pappolla[SUP] 2 [/SUP], Breogán Rodríguez Acevedo[SUP] 2 [/SUP], Luciana Midaglia[SUP] 2 [/SUP], Angela Vidal-Jordana[SUP] 2 [/SUP], Alvaro Cobo-Calvo[SUP] 2 [/SUP], Carmen Tur[SUP] 2 [/SUP], Ingrid Galán[SUP] 2 [/SUP], Joaquín Castilló[SUP] 2 [/SUP], Jordi Río[SUP] 2 [/SUP], Carmen Espejo[SUP] 2 [/SUP], Manuel Comabella[SUP] 2 [/SUP], Carlos Nos[SUP] 2 [/SUP], Jaume Sastre-Garriga[SUP] 2 [/SUP], Mar Tintore[SUP] 2 [/SUP], Xavier Montalban[SUP] 2 [/SUP]
Affiliations
- PMID: 35105687
- DOI: 10.1212/NXI.0000000000001143
Abstract
Background and objectives: Information about humoral and cellular responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and antibody persistence in convalescent (COVID-19) patients with multiple sclerosis (PwMS) is scarce. The objectives of this study were to investigate factors influencing humoral and cellular responses to SARS-CoV-2 and its persistence in convalescent COVID-19 PwMS.
Methods: This is a retrospective study of confirmed COVID-19 convalescent PwMS identified between February 2020 and May 2021 by SARS-CoV-2 antibody testing. We examined relationships between demographics, MS characteristics, disease-modifying therapy (DMT), and humoral (immunoglobulin G against spike and nucleocapsid proteins) and cellular (interferon-gamma [IFN-γ]) responses to SARS-CoV-2.
Results: A total of 121 (83.45%) of 145 PwMS were seropositive, and 25/42 (59.5%) presented a cellular response up to 13.1 months after COVID-19. Anti-CD20-treated patients had lower antibody titers than those under other DMTs (p < 0.001), but severe COVID-19 and a longer time from last infusion increased the likelihood of producing a humoral response. IFN-γ levels did not differ among DMT. Five of 7 (71.4%) anti--CD20-treated seronegative patients had a cellular response. The humoral response persisted for more than 6 months in 41/56(81.13%) PwMS. In multivariate analysis, seropositivity decreased due to anti-CD20 therapy (OR 0.08 [95% CI 0.01-0.55]) and increased in males (OR 3.59 [1.02-12.68]), whereas the cellular response decreased in those with progressive disease (OR 0.04 [0.001-0.88]). No factors were associated with antibody persistence.
Discussion: Humoral and cellular responses to SARS-CoV-2 are present in COVID-19 convalescent PwMS up to 13.10 months after COVID-19. The humoral response decreases under anti-CD20 treatment, although the cellular response can be detected in anti-CD20-treated patients, even in the absence of antibodies.